Global Thalassemia Market Trend, Share, Growth, Size, Analysis and Forecast 2032

Global Thalassemia Market Analysis by Type (Hb Bart Syndrome Or Hemoglobin Bart Hydrops Fetalis Syndrome, Silent Carrier State, Hbh Disease, Trait), by Diagnosis (Prenatal Testing, Perinatal Testing, Pre-Implantation), by Treatment (Iron Chelation, Blood Transfusions, Stem Cell Transplant Or Bone Marrow, Gene Therapy Surgery), by End-User (Pharmaceutical Industries, Biotechnological Laboratories, Hospitals, Educational Research Institutes, Diagnostic Laboratories, Others), and by Region: Global Research Analysis, Latest Industry Insights, Comprehensive Analysis and Forecast 2024-2032

Category: Healthcare Report Format : PDF Pages: 196 Report Code: ZMR-2880 Published Date: Jun-2024 Status : Published

Market Size in 2023	Market Forecast in 2032	CAGR (in %)	Base Year
USD 2844.63 million	USD 4,412.95 million	5.0%	2023

Table Of Content

Chapter 1 Preface
- 1.1 Report Description
- 1.1 Report Scope
Chapter 2 Research Methodology
- 2.1 Research Methodology
- 2.2 Secondary Research
- 2.3 Primary Research
- 2.4 Models
  - 2.4.1 Company Share Analysis Model
  - 2.4.2 Revenue Based Modeling
- 2.5 Research Limitations
Chapter 3 Executive Summary
- 3.1 Global Thalassemia Market, 2016 – 2026 (USD Billion)
- 3.2 Global Thalassemia Market: Snapshot
Chapter 4 Thalassemia Market – Industry Analysis
- 4.1 Introduction
- 4.2 Market Drivers
  - 4.2.1 Driving Factor 1 Analysis
  - 4.2.2 Driving Factor 2 Analysis:
- 4.3 Market Restraints
  - 4.3.1 Restraining Factor Analysis
- 4.4 Market Opportunities
  - 4.4.1 Market Opportunity & Use-case Analysis
  - 4.4.2 Use – Cases for Thalassemia
- 4.5 Porter’s Five Forces Analysis
- 4.6 COVID 19 Impact Analysis
  - 4.6.1.1 Impact on Product Development and Technology Adoption
  - 4.6.1.2 Gap Analysis
Chapter 5 Investment Proposition Analysis
- 5.1 Global Thalassemia Market Attractiveness, By Type
- 5.2 Global Thalassemia Market Attractiveness, By Diagnosis
- 5.3 Global Thalassemia Market Attractiveness, By End-User
- 5.4 Global Thalassemia Market Attractiveness, By Region
Chapter 6 Competitive Landscape
- 6.1 Company Market Share Analysis - 2019
  - 6.1.1 Global Thalassemia Market: Company Market Share, 2019
- 6.2 Strategic Developments
- 7.1 Global Thalassemia Market Overview: by Type
  - 7.1.1 Global Thalassemia Market Revenue Share, by Type, 2019 & 2026
- 7.2 Global Thalassemia Market Analysis/Overview – By Type
  - 7.2.1 Hb Bart Syndrome – Overview/Analysis
  - 7.2.2 Silent Carrier State – Overview/Analysis
  - 7.2.3 Hbh Disease – Overview/Analysis
- 7.3 Hb Bart Syndrome
  - 7.3.1 Global Thalassemia Market for Hb Bart Syndrome, Revenue (USD Billion) 2016 - 2026
- 7.4 Silent Carrier State
  - 7.4.1 Global Thalassemia Market for Silent Carrier State, Revenue (USD Billion) 2016 - 2026
- 7.5 Hbh Disease
  - 7.5.1 Global Thalassemia Market for Hbh Disease, Revenue (USD Billion) 2016 - 2026
- 8.1 Global Thalassemia Market Overview: by Diagnosis
  - 8.1.1 Global Thalassemia Market Revenue Share, by Diagnosis, 2019 & 2026
- 8.2 Global Thalassemia Market Analysis/Overview – By Diagnosis
  - 8.2.1 Prenatal Testing – Overview/Analysis
  - 8.2.2 Perinatal Testing – Overview/Analysis
  - 8.2.3 Pre-Implantation – Overview/Analysis
- 8.3 Prenatal Testing
  - 8.3.1 Global Thalassemia Market for Prenatal Testing, Revenue (USD Billion) 2016 - 2026
- 8.4 Perinatal Testing
  - 8.4.1 Global Thalassemia Market for Perinatal Testing, Revenue (USD Billion) 2016 - 2026
- 8.5 Pre-Implantation
  - 8.5.1 Global Thalassemia Market for Pre-Implantation, Revenue (USD Billion) 2016 - 2026
- 9.1 Global Thalassemia Market Overview: by End-User
  - 9.1.1 Global Thalassemia Market Revenue Share, by End-User, 2019 & 2026
- 9.2 Global Thalassemia Market Analysis/Overview – By End-User
  - 9.2.1 Pharmaceutical Industries – Overview/Analysis
  - 9.2.2 Biotechnulogical Laboratories – Overview/Analysis
  - 9.2.3 Hospital – Overview/Analysis
  - 9.2.4 Educational Research Institutes – Overview/Analysis
  - 9.2.5 Diagnostic Laboratories – Overview/Analysis
  - 9.2.6 Others – Overview/Analysis
- 9.3 Pharmaceutical Industries
  - 9.3.1 Global Thalassemia Market for Pharmaceutical Industries, Revenue (USD Billion) 2016 - 2026
- 9.4 Biotechnulogical Laboratories
  - 9.4.1 Global Thalassemia Market for Biotechnulogical Laboratories, Revenue (USD Billion) 2016 - 2026
- 9.5 Hospital
  - 9.5.1 Global Thalassemia Market for Hospital, Revenue (USD Billion) 2016 - 2026
- 9.6 Educational Research Institutes
  - 9.6.1 Global Thalassemia Market for Educational Research Institutes, Revenue (USD Billion) 2016 - 2026
- 9.7 Diagnostic Laboratories
  - 9.7.1 Global Thalassemia Market for Diagnostic Laboratories, Revenue (USD Billion) 2016 - 2026
- 9.8 Others
  - 9.8.1 Global Thalassemia Market for Others, Revenue (USD Billion) 2016 - 2026
Chapter 10 Thalassemia Market – Regional Analysis
- 10.1 Global Thalassemia Market: Regional Overview
  - 10.1.1 Global Thalassemia Market Revenue Share, by Region, 2019 & 2026
  - 10.1.2 Global Thalassemia Market Revenue, by Region, 2016 – 2026 (USD Billion)
- 10.2 North America
  - 10.2.1 North America Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
  - 10.2.2 North America Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
  - 10.2.3 North America Thalassemia Market Revenue, by Type, 2016 – 2026
  - 10.2.4 North America Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
  - 10.2.5 North America Thalassemia Market Revenue, by End-User, 2016 – 2026
  - 10.2.6 U.S.
  - 10.2.7 Canada
- 10.3 Europe
  - 10.3.1 Europe Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
  - 10.3.2 Europe Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
  - 10.3.3 Europe Thalassemia Market Revenue, by Type, 2016 – 2026
  - 10.3.4 Europe Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
  - 10.3.5 Europe Thalassemia Market Revenue, by End-User, 2016 – 2026
  - 10.3.6 Germany
  - 10.3.7 France
  - 10.3.8 U.K.
  - 10.3.9 Rest of Europe
- 10.4 Asia Pacific
  - 10.4.1 Asia Pacific Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
  - 10.4.2 Asia Pacific Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
  - 10.4.3 Asia Pacific Thalassemia Market Revenue, by Type, 2016 – 2026
  - 10.4.4 Asia Pacific Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
  - 10.4.5 Asia Pacific Thalassemia Market Revenue, by End-User, 2016 – 2026
  - 10.4.6 China
  - 10.4.7 India
  - 10.4.8 Rest of Asia Pacific
- 10.5 Latin America
  - 10.5.1 Latin America Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
  - 10.5.2 Latin America Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
  - 10.5.3 Latin America Thalassemia Market Revenue, by Type, 2016 – 2026
  - 10.5.4 Latin America Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
  - 10.5.5 Latin America Thalassemia Market Revenue, by End-User, 2016 – 2026
  - 10.5.6 Brazil
  - 10.5.7 Rest of Latin America
- 10.6 The Middle-East and Africa
  - 10.6.1 The Middle-East and Africa Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
  - 10.6.2 The Middle-East and Africa Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
  - 10.6.3 The Middle-East and Africa Thalassemia Market Revenue, by Type, 2016 – 2026
  - 10.6.4 The Middle-East and Africa Thalassemia Market Revenue, by Diagnosis, 2016 – 2026
  - 10.6.5 The Middle-East and Africa Thalassemia Market Revenue, by End-User, 2016 – 2026
  - 10.6.6 GCC Countries
  - 10.6.7 Rest of Middle-East Africa
Chapter 11 Company Profiles
- 11.1 Bluebird Bio
  - 11.1.1 Company Overview
  - 11.1.2 Financial Overview
  - 11.1.3 Product Portfolio
  - 11.1.4 Business Strategy
  - 11.1.5 Recent Developments
- 11.2 Lonza Group Ltd
- 11.3 Sangamo Bioscience
- 11.4 Acceleron Pharma, Inc.
- 11.5 Kiadis Pharma

Table Of Figures

List of Figures

FIG. 1 Research Methodology
FIG. 2 Research Methodology – Basic Overview
FIG. 3 Research Methodology – Detailed View
FIG. 4 Global Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
FIG. 5 Porter’s Five Forces Analysis for Global Thalassemia Market
FIG. 6 Global Thalassemia Market Attractiveness, By Type
FIG. 7 Global Thalassemia Market Attractiveness, By Diagnosis
FIG. 8 Global Thalassemia Market Attractiveness, By End-User
FIG. 9 Global Thalassemia Market Attractiveness, By End-User
FIG. 10 Company Share Analysis, 2019
FIG. 11 Global Thalassemia Market Revenue Share, by Type, 2019 & 2026
FIG. 12 Global Thalassemia Market for Hb Bart Syndrome, Revenue (USD Billion) 2016 - 2026
FIG. 13 Global Thalassemia Market for Silent Carrier State, Revenue (USD Billion) 2016 - 2026
FIG. 14 Global Thalassemia Market for Hbh Disease, Revenue (USD Billion) 2016 - 2026
FIG. 15 Global Thalassemia Market Revenue Share, by Diagnosis, 2019 & 2026
FIG. 16 Global Thalassemia Market for Prenatal Testing, Revenue (USD Billion) 2016 - 2026
FIG. 17 Global Thalassemia Market for Perinatal Testing, Revenue (USD Billion) 2016 - 2026
FIG. 18 Global Thalassemia Market for Pre-Implantation, Revenue (USD Billion) 2016 - 2026
FIG. 19 Global Thalassemia Market Revenue Share, by End-User, 2019 & 2026
FIG. 20 Global Thalassemia Market for Pharmaceutical Industries, Revenue (USD Billion) 2016 - 2026
FIG. 21 Global Thalassemia Market for Biotechnological Laboratories, Revenue (USD Billion) 2016 - 2026
FIG. 22 Global Thalassemia Market for Hospital, Revenue (USD Billion) 2016 - 2026
FIG. 23 Global Thalassemia Market for Educational Research Institutes, Revenue (USD Billion) 2016 - 2026
FIG. 24 Global Thalassemia Market for Diagnostic Laboratories, Revenue (USD Billion) 2016 - 2026
FIG. 25 Global Thalassemia Market for Others, Revenue (USD Billion) 2016 - 2026
FIG. 26 Global Thalassemia Market Revenue Share, by Region, 2019 & 2026
FIG. 27 North America Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
FIG. 28 Europe Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
FIG. 29 Asia Pacific Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
FIG. 30 Latin America Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
FIG. 31 The Middle-East and Africa Thalassemia Market Revenue, 2016 - 2026 (USD Billion)
FIG. 32 Bluebird Bio Business Segment Revenue Share, 2018 (%)
FIG. 33 Bluebird Bio Geographical Segment Revenue Share, 2018 (%)

Table Of Tables

List of Tables

TABLE 1 Global Thalassemia Market: Snapshot
TABLE 2 Drivers of the Thalassemia Market: Impact Analysis
TABLE 3 Restraints for the Thalassemia Market: Impact Analysis
TABLE 4 Global Thalassemia Market Revenue, by Region, 2016 – 2026 (USD Billion)
TABLE 5 North America Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
TABLE 6 North America Thalassemia Market Revenue, by Type, 2016 – 2026 (USD Billion)
TABLE 7 North America Thalassemia Market Revenue, by Diagnosis, 2016 – 2026 (USD Billion)
TABLE 8 North America Thalassemia Market Revenue, by End-User, 2016 – 2026 (USD Billion)
TABLE 9 Europe Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
TABLE 10 Europe Thalassemia Market Revenue, by Type, 2016 – 2026 (USD Billion)
TABLE 11 Europe Thalassemia Market Revenue, by Diagnosis, 2016 – 2026 (USD Billion)
TABLE 12 Europe Thalassemia Market Revenue, by End-User, 2016 – 2026 (USD Billion)
TABLE 13 Asia Pacific Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
TABLE 14 Asia Pacific Thalassemia Market Revenue, by Type, 2016 – 2026 (USD Billion)
TABLE 15 Asia Pacific Thalassemia Market Revenue, by Diagnosis, 2016 – 2026 (USD Billion)
TABLE 16 Asia Pacific Thalassemia Market Revenue, by End-User, 2016 – 2026 (USD Billion)
TABLE 17 Latin America Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
TABLE 18 Latin America Thalassemia Market Revenue, by Type, 2016 – 2026 (USD Billion)
TABLE 19 Latin America Thalassemia Market Revenue, by Diagnosis, 2016 – 2026 (USD Billion)
TABLE 20 Latin America Thalassemia Market Revenue, by End-User, 2016 – 2026 (USD Billion)
TABLE 21 The Middle-East and Africa Thalassemia Market Revenue, by Country, 2016 – 2026 (USD Billion)
TABLE 22 The Middle-East and Africa Thalassemia Market Revenue, by Type, 2016 – 2026 (USD Billion)
TABLE 23 The Middle-East and Africa Thalassemia Market Revenue, by Diagnosis, 2016 – 2026 (USD Billion)
TABLE 24 The Middle-East and Africa Thalassemia Market Revenue, by End-User, 2016 – 2026 (USD Billion)

Methodology

FrequentlyAsked Questions

What is Thalassemia Market?

Thalassemia is an exceptional genetic blood disorder majorly characterized by the generation of abnormal hemoglobin, which is accountable for the damage of red blood cells, which mainly lead to anemia. Iron chelation therapies and blood transfusion are the only cure alternatives accessible at present. This gives augment to abundant opportunities and prospects in the market for expansion of the worldwide curative cure for thalassemia.

What was the value of the Thalassemia Market in 2023?

The Thalassemia Market was valued at USD 2844.63 Million in 2023.

What will be the size of the Thalassemia Market in 2032?

The Thalassemia Market is expected to reach USD 4,412.95 Million by 2032, growing at a CAGR of of 5.0% between 2024 to 2032.

What are the key factors driving the Thalassemia Market growth?

Augment in the occurrence of thalassemia is projected to propel market development. In spite of technological developments, the unmet requirement for a consistent treatment alternative still exists. Healing or treatment process of thalassemia is mainly limited to usual iron chelation and blood transfusions therapy. Medicines or drugs prescribed for thalassemia mainly cures symptoms as well as side effects, for instance, iron overload, anemia, and vitamin shortage. On the other hand, gene therapy is up-coming as a consistent treatment choice for the syndrome. The occurrence of thalassemia is expected to augment steadily in the coming years across various regions. This can be accredited to inhabitant’s migration, environmental & genetic, and intermarriages aspects prompting the issue as well as its implications. All these factors are expected to boost the global thalassemia market.

Which are the major companies operating in the Thalassemia Market?

Global Thalassemia Market players such as Bluebird Bio, Lonza Group Ltd., Sangamo Bioscience, Acceleron Pharma, Inc., and Kiadis Pharma., among others.